2nd March 2021
Cambridge, UK – 2 March 2021: Nuformix plc (LSE:NFX), a pharmaceutical development company and drug re-purposing specialist, announces results from a preliminary preclinical study that evaluated NXP002, a proprietary and new physical form of tranilast discovered by Nuformix, in combination with therapies used as standard of care (SOC) in the treatment of idiopathic pulmonary fibrosis (IPF). Download News